
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Wockhardt Q1FY14 Net Sales at Rs.1358 crore and PAT at Rs.324 crore

30 November -0001 | News | By BioSpectrum Bureau

Wockhardt Q1FY14 Net Sales at Rs.1358 crore and PAT at Rs.324 crore



Wockhardt from its quarter end result filed it was clealry observed that Wockhardt increased its research spent significantly and the same is now at 7.2% at Rs. 98 crores and including capital expenditure is at 7.7% to sales for the quarter.

Wockhardt has as of now filed 4 new product applications with USFDA during the quarter. Capital expenditure of Rs. 68 crore was incurred during the quarter.

Business Highlights:

- International Business contributed 82% of the Total Revenues during the quarter.
- Wockhardt's US business recorded a growth of 11% in Q1FY14 and contributed 53% of the Global Revenues for Wockhardt.
- The UK business recorded a growth of 1% IN Q1FY14. The irish market recorded decline of 31%.
- The India business grew by 3% and the Emerging Market business declined by 28% in Q1FY14